• AXL targeting restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through expansion of TCF1+ CD8 T cells 

      Li, Huiyu; Liu, Zhida; Liu, Longchao; Zhang, Hongyi; Han, Chuanhui; Girard, Luc; Park, Hyunsil; Zhang, Anli; Dong, Chunbo; Ye, Jianfeng; Rayford, Austin James; Peyton, Michael; Li, Xiaoguang; Avila, Kimberley; Cao, Xuezhi; Hu, Shuiqing; Alam, Md Maksudul; Akbay, Esra A.; Solis, Luisa M.; Behrens, Carmen; Hernandez-Ruiz, Sharia; Lu, Wei; Wistuba, Ignacio; Heymach, John V.; Chisamore, Michael; Micklem, David Robert; Gabra, Hani; Gausdal, Gro; Lorens, James; Li, Bo; Fu, Yang-Xin; Minna, John D.; Brekken, Rolf A. (Journal article; Peer reviewed, 2022)
      Mutations in STK11/LKB1 in non-small cell lung cancer (NSCLC) are associated with poor patient responses to immune checkpoint blockade (ICB), and introduction of a Stk11/Lkb1 (L) mutation into murine lung adenocarcinomas ...